Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection
- 1 September 1993
- journal article
- research article
- Published by Wiley in Journal of Molecular Recognition
- Vol. 6 (3), 101-109
- https://doi.org/10.1002/jmr.300060302
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Vaccine Protection of Chimpanzees Against Challenge with HIV-1-Infected Peripheral Blood Mononuclear CellsScience, 1992
- Safety and Immunogenicity of a Genetically Engineered Human Immunodeficiency Virus VaccineThe Journal of Infectious Diseases, 1991
- Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.Proceedings of the National Academy of Sciences, 1991
- The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in HumansAnnals of Internal Medicine, 1991
- HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.Proceedings of the National Academy of Sciences, 1990
- Immune response and epitope mapping of a candidate hiv‐1 p17 vaccine hgp30Journal of Clinical Laboratory Analysis, 1990
- Prospects for Prevention of and Early Intervention Against HIVPublished by American Medical Association (AMA) ,1989
- Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Proceedings of the National Academy of Sciences, 1988
- Second Conserved Domain of gp120 Is Important for HIV Infectivity and Antibody NeutralizationScience, 1988
- Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.Proceedings of the National Academy of Sciences, 1987